- CEO
- Hong Li Lin
- Full Time Employees
- 1,142
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 1588 Xinming Road Pinghu ZH China 314200
- IPO Date
- Jun 19, 2014
- Business
- Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. is a China-based pharmaceutical company principally engaged in the research and development, production, and sale of pharmaceutical products. The company offers a comprehensive portfolio including antibiotics, ophthalmology drugs, gynecology products, antipyretic and analgesics, antibacterial and anti-inflammatory drugs, endocrine-related therapies, cardiovascular medications, detoxification products, diuretics, and infusion solutions. These products are available in various forms such as injections, oral solutions, eye drops, tablets, and capsules. Zhejiang Shapuaisi serves primarily the domestic Chinese market with a focus on conditions including blepharitis, meibomian gland inflammation, conjunctivitis, keratitis, and other ocular diseases, as well as broad anti-infective and systemic treatments.
Founded in 1978 and headquartered in Pinghu, Zhejiang Province, the company has developed a strong R&D and manufacturing capability, maintaining a leading position in several therapeutic segments. It was successfully listed on the Shanghai Stock Exchange in 2014. Recent key operational changes include the approval and launch of new ophthalmic products such as levofloxacin eye drops and polyvinyl alcohol eye drops, which are used for treating various eye infections and dry eye symptoms. In 2024, Zhejiang Shapuaisi strategically divested its wholly-owned pharmacy chain subsidiary to focus on its core pharmaceutical manufacturing business. The company has not engaged in major mergers or acquisitions recently but continues to emphasize internal growth and product innovation to strengthen its market presence.
Zhejiang Shapuaisi Pharmaceutical's business segments cover research, manufacturing, and sales across multiple therapeutic areas including antimicrobial, ophthalmic, gynecological, cardiovascular, and anti-inflammatory sectors. The company targets hospitals, pharmacies, and healthcare providers within China, offering a broad product range designed to address both common and specialized medical conditions. Its drug pipeline and product approvals reflect ongoing efforts to expand its ophthalmic and anti-infective offerings supported by regulatory endorsements from China's National Medical Products Administration. This focus positions Zhejiang Shapuaisi as a comprehensive pharmaceutical provider with diversified product lines and a regional market footprint centered in China.